Table 4

Unadjusted and age-adjusted associations (hazard ratio) between Wave 1 HHV-8 seropositivity and prostate cancer at Wave 2 or Wave 3, overall and within strata defined by Wave 1 prostate cancer screening test results

Wave 1 prostate cancer screening test result

Cases

Sub-cohort

Unadjusted

Age-adjusted

Pos

n

Pos

n

HR

95% CI

HR

95% CI

Overall

17

96

46

415

1.46

0.78-2.74

0.88¹

0.46-1.69

PSA (ng/mL)

< 4

12

70

39

392

1.61

0.77-3.38

1.03¹

0.49-2.16

≥ 4

5

26

7

23

0.44

0.11-1.71

0.39²

0.10-1.63

DRE positive or PSA ≥ 4 ng/mL

no

9

54

32

345

1.67

0.72-3.86

1.02¹

0.44-2.39

yes

8

42

14

70

0.85

0.52-2.38

0.59³

0.18-1.91

Pos - number HHV-8 positive, n - case or sub-cohort count, HR - hazard ratio, CI - confidence interval, PSA - prostate-specific antigen, DRE - digital rectal examination

1. Adjusted across four age categories: 40-44, 45-49, 50-59, ≥ 60 years

2. Adjusted across two age categories: 40-59, ≥ 60 years

3. Adjusted across three age categories: 40-49, 50-59, ≥ 60 years

McDonald et al. Infectious Agents and Cancer 2011 6:25   doi:10.1186/1750-9378-6-25